Duesbery NS - Search Results

1

MEK2 is sufficient but not necessary for proliferation and anchorage-independent growth of SK-MEL-28 melanoma cells.

Lee CS, Dykema KJ, Hawkins DM, Cherba DM, Webb CP, Furge KA, Duesbery NS. Lee CS, et al. Among authors: duesbery ns. PLoS One. 2011 Feb 18;6(2):e17165. doi: 10.1371/journal.pone.0017165. PLoS One. 2011. PMID: 21365009 Free PMC article.

2

Consequences and utility of the zinc-dependent metalloprotease activity of anthrax lethal toxin.

Bromberg-White J, Lee CS, Duesbery N. Bromberg-White J, et al. Toxins (Basel). 2010 May;2(5):1038-53. doi: 10.3390/toxins2051038. Epub 2010 May 11. Toxins (Basel). 2010. PMID: 22069624 Free PMC article. Review.

3

Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma.

Ding Y, Boguslawski EA, Berghuis BD, Young JJ, Zhang Z, Hardy K, Furge K, Kort E, Frankel AE, Hay RV, Resau JH, Duesbery NS. Ding Y, et al. Among authors: duesbery ns. Mol Cancer Ther. 2008 Mar;7(3):648-58. doi: 10.1158/1535-7163.MCT-07-2229. Epub 2008 Mar 4. Mol Cancer Ther. 2008. PMID: 18319331

4

Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.

Andersen NJ, Nickoloff BJ, Dykema KJ, Boguslawski EA, Krivochenitser RI, Froman RE, Dawes MJ, Baker LH, Thomas DG, Kamstock DA, Kitchell BE, Furge KA, Duesbery NS. Andersen NJ, et al. Among authors: duesbery ns. Mol Cancer Ther. 2013 Sep;12(9):1701-14. doi: 10.1158/1535-7163.MCT-12-0893. Epub 2013 Jun 26. Mol Cancer Ther. 2013. PMID: 23804705 Free PMC article.

5

Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms.

Monsma DJ, Cherba DM, Eugster EE, Dylewski DL, Davidson PT, Peterson CA, Borgman AS, Winn ME, Dykema KJ, Webb CP, MacKeigan JP, Duesbery NS, Nickoloff BJ, Monks NR. Monsma DJ, et al. Among authors: duesbery ns. Am J Cancer Res. 2015 Mar 15;5(4):1507-18. eCollection 2015. Am J Cancer Res. 2015. PMID: 26101714 Free PMC article.

6

Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways.

Duesbery NS, Resau J, Webb CP, Koochekpour S, Koo HM, Leppla SH, Vande Woude GF. Duesbery NS, et al. Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4089-94. doi: 10.1073/pnas.061031898. Epub 2001 Mar 20. Proc Natl Acad Sci U S A. 2001. PMID: 11259649 Free PMC article.

7

Identification of VEGF-independent cytokines in proliferative diabetic retinopathy vitreous.

Bromberg-White JL, Glazer L, Downer R, Furge K, Boguslawski E, Duesbery NS. Bromberg-White JL, et al. Among authors: duesbery ns. Invest Ophthalmol Vis Sci. 2013 Oct 3;54(10):6472-80. doi: 10.1167/iovs.13-12518. Invest Ophthalmol Vis Sci. 2013. PMID: 24003089

8

Oculoectodermal syndrome is a mosaic RASopathy associated with KRAS alterations.

Peacock JD, Dykema KJ, Toriello HV, Mooney MR, Scholten DJ 2nd, Winn ME, Borgman A, Duesbery NS, Hiemenga JA, Liu C, Campbell S, Nickoloff BP, Williams BO, Steensma M. Peacock JD, et al. Among authors: duesbery ns. Am J Med Genet A. 2015 Jul;167(7):1429-35. doi: 10.1002/ajmg.a.37048. Epub 2015 Mar 21. Am J Med Genet A. 2015. PMID: 25808193

9

Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor.

Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD, Ahn NG, Oskarsson MK, Fukasawa K, Paull KD, Vande Woude GF. Duesbery NS, et al. Science. 1998 May 1;280(5364):734-7. doi: 10.1126/science.280.5364.734. Science. 1998. PMID: 9563949

10

MEK wars, a new front in the battle against cancer.

Duesbery NS, Webb CP, Vande Woude GF. Duesbery NS, et al. Nat Med. 1999 Jul;5(7):736-7. doi: 10.1038/10457. Nat Med. 1999. PMID: 10395314 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

54 results

Search Page